Assia Chemical Industries Ltd.

Teva Pharmaceutical Industries Limited

Sharona Shachan-Tov

Rotem Sella-Erez

Tamar Nidam

Maytal Piran

Ariel Mittelman

Valerie Niddam-Hildesheim

Doron Rudik

Yifat Ronen

Alexander Mainfeld

Sigalit Levi

Natalia Shenkar

Ofir Shaul

Eli Lancry

Jonathan Enav

Ido Fuchs

Marina Yarovoy

Motti Erlich

Jenny Goldshtein

Einat Kisin-Finfer

Oshrat Frenkel

Abed Masarwa

Victoria Machtey

Sagit Azran

Rotem Sella-erez

The present disclosure encompasses crystalline polymorphs of Pracinostat and of Pracinostat salts, and pharmaceutical compositions thereof.

Crystalline polymorphs of Pracinostat and Pracinostat salts

Salts and solid state forms of Larotrectinib, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.

Crystalline form E1 of larotrectinib ethanesulfonate

Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.

Solid state forms of valbenazine

Disclosed are solid state forms of Netarsudil mesylate, processes for preparation thereof, uses thereof, and pharmaceutical compositions thereof.

Solid state forms of netarsudil mesylate

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.

Crystal forms of O-desmethylvenlafaxine fumarate

The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.

Processes for the synthesis of O-desmethylvenlafaxine

Growing community of inventors

Kfar-Saba, Israel

Sharona Shachan-Tov